Total randomized
N=122

**Everolimus 1.5mg**
N=61

- 9 Discontinued study medication, (14.8%)
  - 2 Adverse events
  - 6 Unsatisfactory therapeutic effect
  - 1 Subject withdrew consent

- 5 Discontinued study
  - 5 Subject withdrew consent

**Month12**
- 56 Completed study phase (91.8%)
- 52 Completed study medication (85.2%)

**MMF 2g/day**
N=61

- 8 Discontinued study medication, (13.1%)
  - 1 Adverse events
  - 3 Unsatisfactory therapeutic effect
  - 4 Subject withdrew consent

- 3 Discontinued study
  - 3 Subject withdrew consent

**Month12**
- 58 Completed study phase (95.1%)
- 53 Completed study medication (86.9%)